PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Budesonide - Nephropathy

PAD Profile : Budesonide - Nephropathy

Keywords :
targeted-release budesonide, primary IgA nephropathy
Brand Names Include :
Kinpeygo

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Modified release capsules
Important Information :
Not interchangeable with other budesonide preparations
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves targeted-release budesonide (Kinpeygo®) for treating primary IgA nephropathy in line with the recommendations made in NICE TA937. Targeted-release budesonide (Kinpeygo®) for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians). Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

06. Endocrine System
06.03.02. Glucocorticoid therapy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More